soul trial oral semaglutide cardiovascular outcomes results 2025 Lowers Events by 14% in Type 2 Diabetes Patients with Heart, Kidney Disease SOUL: Oral Semaglutide Bests Usual

NICE has published technology appraisals for licensed GLP-1-based medicines used in weight management, including TA875 (semaglutide 2.4 mg for managing overweight and obesity)

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK

Professor MacIsaac was a recipient of St Vincents Hospital Research Endowment Fund 20212023 and the Australian Governments Medical Research Future Fund (established by MTPConnects Targeted Transition Research Accelerator initiative)

Severe pain initially, then decreased due to nerve damage

However, SNRIs may also present a higher risk of certain side effects, such as increased blood pressure and heart rate, compared to SSRIs